Market LIVE
Published markets; coverage varies by country
Product profile · United States

VICTOZA

 ·  Patent Litigation & Settlement History ↓

IngredientLIRAGLUTIDE
Application typeNDA
Application022341
Product001
Dosage formSOLUTION
RouteSUBCUTANEOUS
Strength18MG/3ML (6MG/ML)
Approval date2010-01-25
Marketing statusPrescription
Status event—
ApplicantNOVO NORDISK INC
Product source

Current GenericRadar decision

Year2024
SelectionEXISTING_GENERIC
ReviewDISQUALIFIED
Anchor typeFINAL_ANDA
Anchor date2024-12-23
Patent anchor—
Exclusivity anchor—
Protection date—
First Final ANDA2024-12-23
Status event—

Exact product/strength Final ANDA confirmed. Date is earliest verified official product approval for the batch. AG and tentative excluded. Approval date is not commercial launch date. No DS classification asserted.

Patent estate

PatentEffective dateOfficial listingTRUE_DSDS gradeClaim classification / basisPTEPEDFamily
81148332025-08-13DS/DP ————
———
81148332026-02-13— ————
—2026-02-13—
99686592037-01-09U U-2313———
———
99686592037-07-09— ————
—2037-07-09—

Regulatory exclusivity

CodeStart dateEnd dateScopeEntire productAll indicationsFull coverage dateCombinationSource
No exclusivity facts are recorded in this product snapshot.

2026-10-10 · NO_RECORD_IN_CURRENT_SNAPSHOT · Historical coverage: NOT_COMPLETE

Generic approval evidence

Application / productEventFinal dateTentative dateApplicantAuthorized genericExact mappingSource
215503 / 001FINAL_APPROVAL · FINAL_APPROVED2024-12-23—HIKMA PHARMACEUTICALS USA INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
218115 / 001FINAL_APPROVAL · FINAL_APPROVED2025-04-02—NANJING KING FRIEND BIOCHEMICAL PHARMACEUTICAL CO LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
215421 / 001FINAL_APPROVAL · FINAL_APPROVED2025-07-22—LUPIN LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
214568 / 001FINAL_APPROVAL · FINAL_APPROVED2025-08-27—TEVA PHARMACEUTICALS DEVELOPMENT INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
217590 / 001FINAL_APPROVAL · FINAL_APPROVED2026-01-14—ORBICULAR PHARMACEUTICAL TECHNOLOGIES PRIVATE LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
217063 / 001FINAL_APPROVAL · FINAL_APPROVED2026-02-24—BIOCON PHARMA LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
217234 / 001FINAL_APPROVAL · FINAL_APPROVED2026-02-24—ORBICULAR PHARMACEUTICAL TECHNOLOGIES PRIVATE LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
215245 / 001FINAL_APPROVAL · FINAL_APPROVED2026-03-11—BIOCON PHARMA LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
212552 / 001FINAL_APPROVAL · FINAL_APPROVED2026-03-30—FRESENIUS KABI USA LLCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
213155 / 001FINAL_APPROVAL · FINAL_APPROVED2026-06-15—MYLAN INSTITUTIONAL LLCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
212972 / 001FINAL_APPROVAL · FINAL_APPROVED2026-07-01—SANDOZ INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource

Market Entry Information

API filings, authorized generics and linked regulatory milestones.

API Master Files & Certifications 0 records

Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.

APIHolder / manufacturerHolder countryFiling typeNumberStatusFiled dateAvailable for referenceSourceLast verified
No master-file or certification records are linked through public manufacturer portfolios.

Authorized Generics 0 records

Authorized generics are shown separately from independent ANDA approvals.

Application / productApplicantEvent / status First marketed Product mappingSourceLast verified
No authorized-generic records are linked to this product.

Tentative ANDA Approvals 0 records

Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.

Application / productApplicantEvent / status Tentative date Follow-up final approvalProduct mappingSourceLast verified
No tentative-approval records are linked to this product.

Paragraph IV Challenges 0 records

Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.

Application / productApplicantEvent / status Certification event date Product mappingSourceLast verified
No structured Paragraph IV certification events are linked in the available approval evidence.

Final ANDA Approvals 11 records

Approval dates do not establish commercial launch. Product mapping is shown for each linked record.

Application / productApplicantEvent / status Final approval date Product mappingSourceLast verified
215503 / 001HIKMA PHARMACEUTICALS USA INCFINAL_APPROVAL · FINAL_APPROVED2024-12-23 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
218115 / 001NANJING KING FRIEND BIOCHEMICAL PHARMACEUTICAL CO LTDFINAL_APPROVAL · FINAL_APPROVED2025-04-02 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
215421 / 001LUPIN LTDFINAL_APPROVAL · FINAL_APPROVED2025-07-22 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
214568 / 001TEVA PHARMACEUTICALS DEVELOPMENT INCFINAL_APPROVAL · FINAL_APPROVED2025-08-27 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
217590 / 001ORBICULAR PHARMACEUTICAL TECHNOLOGIES PRIVATE LTDFINAL_APPROVAL · FINAL_APPROVED2026-01-14 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
217063 / 001BIOCON PHARMA LTDFINAL_APPROVAL · FINAL_APPROVED2026-02-24 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
217234 / 001ORBICULAR PHARMACEUTICAL TECHNOLOGIES PRIVATE LTDFINAL_APPROVAL · FINAL_APPROVED2026-02-24 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
215245 / 001BIOCON PHARMA LTDFINAL_APPROVAL · FINAL_APPROVED2026-03-11 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
212552 / 001FRESENIUS KABI USA LLCFINAL_APPROVAL · FINAL_APPROVED2026-03-30 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
213155 / 001MYLAN INSTITUTIONAL LLCFINAL_APPROVAL · FINAL_APPROVED2026-06-15 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
212972 / 001SANDOZ INCFINAL_APPROVAL · FINAL_APPROVED2026-07-01 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
Decision evidence (1)
TypeDateRoleBasisSource
GENERIC2024-12-23TERMINAL_GENERIC_BASISExact product/strength Final ANDA confirmed. Date is earliest verified official product approval for the batch. AG and tentative excluded. Approval date is not commercial launch date. No DS classification asserted.Source
Independent legal-event information

Litigation & Settlement History

Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.

No litigation or settlement record currently linked to this product.